{"doi":"10.3390/v15020567","title":"Definition of a New HLA B*52-Restricted Rev CTL Epitope Targeted by an HIV-1-Infected Controller","abstract":"The analysis of T-cell responses in HIV-1-infected controllers may contribute to a better understanding of the protective components of the immune system. Here, we analyzed the HIV-1-specific T-cell response in a 59-year-old HIV-1-infected controller, infected for at least seven years, who presented with low viral loads ranging from <20 copies/mL to 200 copies/mL and normal CD4 counts of >800 cells/µL. In γ-IFN-ELISpot assays using freshly isolated PBMCs, he displayed a very strong polyclonal T-cell response to eight epitopes in Gag, Nef and Rev; with the dominant responses directed against the HLA-B*57-epitope AISPRTLNAW and against a so-far-unknown epitope within Rev. Further analyses using peptide-stimulated T-cell lines in γ-IFN-ELISpot assays delineated the peptide RQRQIRSI (Rev-RI8) as a newly defined HLA-B*52-restricted epitope located within a functionally important region of Rev. Peptide-stimulation assays in 15 HLA-B*52-positive HIV-1-infected subjects, including the controller, demonstrated recognition of the Rev-RI8 epitope in 6/15 subjects. CD4 counts before the start of antiviral therapy were significantly higher in subjects with recognition of the Rev-RI8 epitope. Targeting of the Rev-RI8 epitope in Rev by CTL could contribute to the positive association of HLA-B*52 with a more favorable course of HIV-1-infection.","journal":"Viruses","year":2023,"id":384656,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9585,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1152121,"name":"Katja Schmidt","orcid":"0000-0002-0973-6933","position":1,"is_corresponding":false},{"id":1152122,"name":"Victoria K. Ogungbemi-Alt","orcid":"0000-0002-8730-4749","position":2,"is_corresponding":false},{"id":745624,"name":"Silke Bergmann","orcid":null,"position":3,"is_corresponding":false},{"id":1152123,"name":"Philipp Steininger","orcid":"0000-0002-4493-4556","position":4,"is_corresponding":false},{"id":1152124,"name":"Klaus Korn","orcid":"0000-0003-1891-2107","position":5,"is_corresponding":false},{"id":1152525,"name":"Bernd M. Spriewald","orcid":null,"position":6,"is_corresponding":false},{"id":1125892,"name":"Ellen G. Harrer","orcid":null,"position":7,"is_corresponding":false},{"id":644924,"name":"Krystelle Nganou‐Makamdop","orcid":"0000-0003-4839-2886","position":8,"is_corresponding":false},{"id":1016771,"name":"Thomas Harrer","orcid":"0000-0001-6945-3241","position":9,"is_corresponding":false},{"id":1152524,"name":"Boutaina El Kenz","orcid":null,"position":0,"is_corresponding":true}],"reference_count":40,"raw_metadata":null,"created_at":"2026-07-19T01:17:37.110513Z","pmid":"36851781","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}